Additionally, the 36-month beta value for STRO is 1.15. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for STRO is 76.30M and currently, short sellers hold a 4.13% ratio of that float. The average trading volume of STRO on January 16, 2025 was 960.25K shares.
STRO) stock’s latest price update
The stock price of Sutro Biopharma Inc (NASDAQ: STRO) has dropped by -4.64 compared to previous close of 1.83. Despite this, the company has seen a fall of -10.51% in its stock price over the last five trading days. globenewswire.com reported 2025-01-07 that SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.
STRO’s Market Performance
STRO’s stock has fallen by -10.51% in the past week, with a monthly drop of -17.69% and a quarterly drop of -54.44%. The volatility ratio for the week is 7.35% while the volatility levels for the last 30 days are 7.87% for Sutro Biopharma Inc The simple moving average for the past 20 days is -7.71% for STRO’s stock, with a -50.76% simple moving average for the past 200 days.
Analysts’ Opinion of STRO
Many brokerage firms have already submitted their reports for STRO stocks, with BofA Securities repeating the rating for STRO by listing it as a “Buy.” The predicted price for STRO in the upcoming period, according to BofA Securities is $12 based on the research report published on May 08, 2024 of the previous year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see STRO reach a price target of $12. The rating they have provided for STRO stocks is “Buy” according to the report published on November 09th, 2023.
Oppenheimer gave a rating of “Outperform” to STRO, setting the target price at $10 in the report published on October 06th of the previous year.
STRO Trading at -32.09% from the 50-Day Moving Average
After a stumble in the market that brought STRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.53% of loss for the given period.
Volatility was left at 7.87%, however, over the last 30 days, the volatility rate increased by 7.35%, as shares sank -15.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.70% lower at present.
During the last 5 trading sessions, STRO fell by -10.26%, which changed the moving average for the period of 200-days by -67.14% in comparison to the 20-day moving average, which settled at $1.8910. In addition, Sutro Biopharma Inc saw -5.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at STRO starting from Vasquez Nicki, who sale 12,185 shares at the price of $5.00 back on Jan 29 ’24. After this action, Vasquez Nicki now owns 12,803 shares of Sutro Biopharma Inc, valued at $60,925 using the latest closing price.
Stock Fundamentals for STRO
Current profitability levels for the company are sitting at:
- -0.81 for the present operating margin
- 0.59 for the gross margin
The net margin for Sutro Biopharma Inc stands at -0.77. The total capital return value is set at -0.41. Equity return is now at value -110.89, with -28.06 for asset returns.
Based on Sutro Biopharma Inc (STRO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -4.25. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -3.71.
Currently, EBITDA for the company is -67.92 million with net debt to EBITDA at 1.82. When we switch over and look at the enterprise to sales, we see a ratio of -0.02. The receivables turnover for the company is 24.19for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.09.
Conclusion
In conclusion, Sutro Biopharma Inc (STRO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
